28071754|t|Far-infrared protects vascular endothelial cells from advanced glycation end products - induced injury via PLZF -mediated autophagy in diabetic mice
28071754|a|The accumulation of advanced glycation end products (AGEs) in diabetic patients induces vascular endothelial injury. Promyelocytic leukemia zinc finger protein (PLZF) is a transcription factor that can be activated by low-temperature far-infrared (FIR) irradiation to exert beneficial effects on the vascular endothelium. In the present study, we investigated the influence of FIR - induced PLZF activation on AGE - induced endothelial injury both in vitro and in vivo. FIR irradiation inhibited AGE - induced apoptosis in human umbilical vein endothelial cells (HUVECs). PLZF activation increased the expression of phosphatidylinositol-3 kinases (PI3K), which are important kinases in the autophagic signaling pathway. FIR - induced PLZF activation led to autophagy in HUVEC, which was mediated through the upregulation of PI3K. Immunofluorescence staining showed that AGEs were engulfed by HUVECs and localized to lysosomes. FIR - induced autophagy promoted AGEs degradation in HUVECs. In nicotinamide / streptozotocin - induced diabetic mice, FIR therapy reduced serum AGEs and AGEs deposition at the vascular endothelium. FIR therapy also reduced diabetes - induced inflammatory markers in the vascular endothelium and improved vascular endothelial function. These protective effects of FIR therapy were not found in PLZF - knockout mice. Our data suggest that FIR - induced PLZF activation in vascular endothelial cells protects the vascular endothelium in diabetic mice from AGE - induced injury.
28071754	22	48	vascular endothelial cells	T017	UMLS:C1257792
28071754	54	85	advanced glycation end products	T103	UMLS:C0162574
28071754	96	102	injury	T037	UMLS:C0178314
28071754	107	111	PLZF	T103	UMLS:C1674035
28071754	122	131	autophagy	T038	UMLS:C0004391
28071754	135	148	diabetic mice	T204	UMLS:C0085243
28071754	169	200	advanced glycation end products	T103	UMLS:C0162574
28071754	202	206	AGEs	T103	UMLS:C0162574
28071754	211	219	diabetic	T038	UMLS:C0011847
28071754	237	257	vascular endothelial	T017	UMLS:C0014261
28071754	258	264	injury	T037	UMLS:C0178314
28071754	266	308	Promyelocytic leukemia zinc finger protein	T103	UMLS:C1674035
28071754	310	314	PLZF	T103	UMLS:C1674035
28071754	321	341	transcription factor	T103	UMLS:C0040648
28071754	354	363	activated	T038	UMLS:C2253861
28071754	417	441	exert beneficial effects	T038	UMLS:C3714634
28071754	449	469	vascular endothelium	T017	UMLS:C0014261
28071754	486	491	study	T062	UMLS:C2603343
28071754	540	544	PLZF	T103	UMLS:C1674035
28071754	545	555	activation	T038	UMLS:C2253861
28071754	559	562	AGE	T103	UMLS:C0162574
28071754	573	584	endothelial	T017	UMLS:C0014261
28071754	585	591	injury	T037	UMLS:C0178314
28071754	645	648	AGE	T103	UMLS:C0162574
28071754	659	668	apoptosis	T038	UMLS:C0162638
28071754	672	710	human umbilical vein endothelial cells	T017	UMLS:C3179121
28071754	712	718	HUVECs	T017	UMLS:C3179121
28071754	721	725	PLZF	T103	UMLS:C1674035
28071754	726	736	activation	T038	UMLS:C2253861
28071754	751	761	expression	T038	UMLS:C1171362
28071754	765	795	phosphatidylinositol-3 kinases	T103	UMLS:C2936824
28071754	797	801	PI3K	T103	UMLS:C2936824
28071754	824	831	kinases	T103	UMLS:C0031727
28071754	839	849	autophagic	T038	UMLS:C0004391
28071754	850	867	signaling pathway	T038	UMLS:C0037080
28071754	883	887	PLZF	T103	UMLS:C1674035
28071754	888	898	activation	T038	UMLS:C2253861
28071754	906	915	autophagy	T038	UMLS:C0004391
28071754	919	924	HUVEC	T017	UMLS:C3179121
28071754	957	969	upregulation	T038	UMLS:C0041904
28071754	973	977	PI3K	T103	UMLS:C2936824
28071754	979	997	Immunofluorescence	T058	UMLS:C0016318
28071754	998	1006	staining	T058	UMLS:C0487602
28071754	1019	1023	AGEs	T103	UMLS:C0162574
28071754	1041	1047	HUVECs	T017	UMLS:C3179121
28071754	1052	1061	localized	T082	UMLS:C0392752
28071754	1065	1074	lysosomes	T017	UMLS:C0024369
28071754	1090	1099	autophagy	T038	UMLS:C0004391
28071754	1109	1113	AGEs	T103	UMLS:C0162574
28071754	1129	1135	HUVECs	T017	UMLS:C3179121
28071754	1140	1152	nicotinamide	T103	UMLS:C0028027
28071754	1155	1169	streptozotocin	T103	UMLS:C0038432
28071754	1180	1193	diabetic mice	T204	UMLS:C0085243
28071754	1199	1206	therapy	T058	UMLS:C0087111
28071754	1215	1225	serum AGEs	T103	UMLS:C0217068
28071754	1230	1234	AGEs	T103	UMLS:C0162574
28071754	1253	1273	vascular endothelium	T017	UMLS:C0014261
28071754	1279	1286	therapy	T058	UMLS:C0087111
28071754	1300	1308	diabetes	T038	UMLS:C0011847
28071754	1319	1339	inflammatory markers	T033	UMLS:C4087233
28071754	1347	1367	vascular endothelium	T017	UMLS:C0014261
28071754	1372	1380	improved	T033	UMLS:C0184511
28071754	1381	1401	vascular endothelial	T017	UMLS:C0014261
28071754	1418	1436	protective effects	T038	UMLS:C3179279
28071754	1444	1451	therapy	T058	UMLS:C0087111
28071754	1457	1466	not found	T033	UMLS:C0442737
28071754	1470	1474	PLZF	T103	UMLS:C1674035
28071754	1477	1490	knockout mice	T204	UMLS:C0206745
28071754	1528	1532	PLZF	T103	UMLS:C1674035
28071754	1533	1543	activation	T038	UMLS:C2253861
28071754	1547	1573	vascular endothelial cells	T017	UMLS:C1257792
28071754	1587	1607	vascular endothelium	T017	UMLS:C0014261
28071754	1611	1624	diabetic mice	T204	UMLS:C0085243
28071754	1630	1633	AGE	T103	UMLS:C0162574
28071754	1644	1650	injury	T037	UMLS:C0178314